Veraxa Biotech Holding AG (FRA:J8L0) Other Stockholders Equity: €-0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J8L0 Veraxa Biotech Holding AG FRA:J8L0
13 GF Score
Price €1.62
! 2 Warning Signs
View Full Analysis

What is Veraxa Biotech Holding AG Other Stockholders Equity?

Veraxa Biotech Holding AG FRA:J8L0 -2.06% 13 Other Stockholders Equity is €-0.00 Mil as of Dec. 2025. GuruFocus rates FRA:J8L0 with a GF Score™ of 13/100. The stock has 2 warning signs investors should review.

Veraxa Biotech Holding AG's Other Stockholders Equity for the quarter that ended in Dec. 2025 was €-0.00 Mil.

Veraxa Biotech Holding AG's quarterly Other Stockholders Equity increased from Dec. 2024 (€0.00 Mil) to Jun. 2025 (€0.00 Mil) but then declined from Jun. 2025 (€0.00 Mil) to Dec. 2025 (€-0.00 Mil).

Veraxa Biotech Holding AG's annual Other Stockholders Equity declined from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.00 Mil) and declined from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€-0.00 Mil).

Veraxa Biotech Holding AG Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Veraxa Biotech Holding AG's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veraxa Biotech Holding AG Other Stockholders Equity Chart

Veraxa Biotech Holding AG Annual Data
Trend Dec23 Dec24 Dec25
Other Stockholders Equity
0.00 0.00 -0.00

Veraxa Biotech Holding AG Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity 0.00 0.00 0.00 0.00 -0.00
FRA:J8L0
13GF Score
Veraxa Biotech Holding AG FRA:J8L0
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veraxa Biotech Holding AG Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €-0.00 Mil mean?
Veraxa Biotech Holding AG (FRA:J8L0) has a Other Stockholders Equity of €-0.00 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Veraxa Biotech Holding AG and its competitors.
Is Veraxa Biotech Holding AG's Other Stockholders Equity too high?
Veraxa Biotech Holding AG's current Other Stockholders Equity is €-0.00 Mil. Overall, Veraxa Biotech Holding AG has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Veraxa Biotech Holding AG's Other Stockholders Equity compare to TTRX and IRD?
Veraxa Biotech Holding AG's Other Stockholders Equity of €-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Veraxa Biotech Holding AG and its competitors. Veraxa Biotech Holding AG's current Other Stockholders Equity is €-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veraxa Biotech Holding AG stock overvalued right now?
Veraxa Biotech Holding AG (FRA:J8L0) has a current Other Stockholders Equity of €-0.00 Mil. The current Other Stockholders Equity is €-0.00 Mil. Veraxa Biotech Holding AG's overall GF Score™ is 13/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Veraxa Biotech Holding AG (FRA:J8L0), the current Other Stockholders Equity is €-0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veraxa Biotech Holding AG Business Description

Other Exchanges VRXA:USA
Address Talacker 35, Zurich, CHE, 8001
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
13GF Score

Get the complete analysis for FRA:J8L0

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.62
Price